HK Stock Market Move | | Most pharmaceutical stocks under pressure this morning; short-term external interest rate disturbances remain; innovative drugs enter a "realization stage" of multiple validations

date
11:55 18/11/2026
avatar
GMT Eight
Most pharmaceutical stocks came under pressure this morning, with CRO and innovative drug stocks leading the declines. As of press time, Joinn Laboratories (06127) fell 9.11% to HK$19.76, while Asymchem Laboratories (06821) dropped 6.26% to HK$107.8.
Most pharmaceutical stocks came under pressure this morning, with CRO and innovative drug stocks leading the declines. As of press time, Joinn Laboratories (06127) fell 9.11% to HK$19.76; Asymchem Laboratories (06821) fell 6.26% to HK$107.8; Hangzhou Tigermed Consulting (03347) fell 5.12% to HK$33.34; 3SBIO (01530) fell 4.55% to HK$13.23; INNOVENT BIO (01801) fell 3.61% to HK$82.7. Zhongtai believes that, against the backdrop of lingering external interest rate disturbances, marginal signals such as improvement on the domestic payment side, continued high prosperity in BD, and weakening geopolitical disturbances for CXO continue to validate the fundamental resilience of innovative drugs and the industry chain. The bank judges that the valuation repair of the pharmaceutical innovation chain has sustainability, and recommends downplaying the short-term disturbances from overseas interest rate fluctuations and actively focusing on: 1) the innovative drug sector: with marginal improvement in the domestic payment environment, attention should be paid to companies with blockbuster innovative drugs that have been successfully included in the reimbursement scope in this round and have ample commercialization elasticity; 2) AI pharma + CXO: attention should be paid to the AIDD elasticity theme, which has dense event catalysts and rapidly evolving industry narratives; 3) valuation transition: low-position defensive assets whose valuations have fully digested negative factors earlier and which have fundamental repair expectations. In addition, recent market analysis pointed out that the short-term setback of a single product from a pharmaceutical company does not mean that the globalization process of Chinese innovative drugs will come to a halt. Chinese innovative drugs going overseas have bid farewell to the "expectation trading" stage, which focused only on the number of BD deals and total potential transaction value, and have entered a "realization stage" jointly tested by global clinical data, regulatory approvals, and commercial sales.